|
Market Closed -
Nasdaq
23:00:00 30/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 19.75 USD | -0.25% |
|
+0.41% | +224.84% |
| 10-20 | Health Care Up on Deal Activity - Health Care Roundup | DJ |
| 10-19 | Silence Therapeutics to Be Acquired by Germany's Merck in $1.3 Billion Deal; Shares Surge | MT |
Company Valuation: Silence Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 528 | 454.3 | 527.3 | 259.5 | 213.4 | 887.6 | - | - |
| Change | - | -13.96% | 16.08% | -50.8% | -17.76% | 315.99% | - | - |
| Enterprise Value (EV) 1 | 454.5 | 454.3 | 473.6 | 163.4 | 149.5 | 753.2 | 711.8 | 655.3 |
| Change | - | -0.04% | 4.24% | -65.49% | -8.53% | 403.82% | -5.5% | -7.94% |
| P/E | -13.7x | -9.99x | -11.6x | -6.95x | -3.22x | -38.7x | -31.9x | -24.4x |
| PBR | - | - | 29.5x | -7.12x | 13.8x | 19.8x | 13.3x | 10.6x |
| PEG | - | 0.8x | 4.94x | 0.2x | -0x | 0.5x | -1.5x | -0.8x |
| Capitalization / Revenue | 42.5x | 26x | 20.8x | 7.57x | 510x | 2,700x | 1,167x | 5,126x |
| EV / Revenue | 36.6x | 26x | 18.7x | 4.77x | 357x | 2,291x | 936x | 3,784x |
| EV / EBITDA | -10x | -9.44x | -9.64x | -3.29x | -2.2x | -16.7x | -11.8x | -8.45x |
| EV / EBIT | -9.92x | -9.35x | -9.55x | -3.26x | -2.19x | -16.7x | -10.9x | -7.56x |
| EV / FCF | 419x | -9.96x | -10.4x | -3.04x | -3x | -22.4x | -10.2x | -7.44x |
| FCF Yield | 0.24% | -10% | -9.63% | -32.9% | -33.4% | -4.46% | -9.78% | -13.4% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | -1.742 | -1.527 | -1.491 | -0.99 | -1.89 | -0.51 | -0.62 | -0.81 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 12.42 | 17.5 | 25.38 | 34.27 | 0.4183 | 0.3288 | 0.7604 | 0.1732 |
| EBITDA 1 | -45.39 | -48.11 | -49.11 | -49.69 | -68.06 | -45.15 | -60.24 | -77.53 |
| EBIT 1 | -45.81 | -48.59 | -49.6 | -50.16 | -68.16 | -45.2 | -65.14 | -86.63 |
| Net income 1 | -39.41 | -40.49 | -43.27 | -35.89 | -66.32 | -42.57 | -64.86 | -88.47 |
| Net Debt 1 | -73.54 | - | -53.76 | -96.03 | -63.87 | -134.4 | -175.8 | -232.3 |
| Reference price 3 | 23.89 | 15.25 | 17.37 | 6.88 | 6.08 | 19.75 | 19.75 | 19.75 |
| Nbr of stocks (in thousands) | 29,928 | 35,893 | 38,670 | 47,215 | 47,234 | 60,209 | - | - |
| Announcement Date | 3/17/22 A | 3/15/23 A | 3/13/24 A | 2/27/25 A | 3/5/26 A | - | - | - |
1USD in Million2GBP in Million3USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -38.73x | 2291.15x | -16.68x | - | 1.19B | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -71.62x | 13.03x | -68.47x | -.--% | 24.7B | |
| Average | 11.73x | 254.33x | 4.71x | 0.34% | 39.55B | |
| Weighted average by Cap. | 21.46x | 33.14x | 11.15x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- SLN Stock
- Valuation Silence Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
